Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pietschmann

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
Antimicrobial Resistance and Infection Control|February 17, 2018
Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological diseaseClaas Baier, Sibylle Haid, Andreas Beilken, et al.
Plos One|September 13, 2011
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virusThomas von Hahn, Andreas Schulze, Ivan Chicano Wust, et al.
Journal of Virology|November 11, 2011
Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitopeMarianne Ruhl, Patrick Chhatwal, Heiko Strathmann, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33Alexander W Tarr, Ania M Owsianka, Judith M Timms, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Adapted hepatitis C virus clone infects innate immunity-deficient mouse hepatocytes with minimal human HCV entry factorsJulie Ann Sheldon, Melina Winkler, Qinggong Yuan, et al.
Plos One|July 12, 2014
Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodiesMilena Lange, Melanie Fiedler, Dorothea Bankwitz, et al.
Mbio|May 18, 2017
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2Ieva Vasiliauskaite, Ania Owsianka, Patrick England, et al.
European Journal of Medicinal Chemistry|April 8, 2025
Unlocking the antiviral arsenal: Structure-guided optimization of small-molecule inhibitors against RSV and hCoV-229EChristina Karhan, Svenja M Sake, Antonia P Gunesch, et al.
Angewandte Chemie (International Ed. in English)|November 24, 2022
Persicamidines-Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against CoronavirusesLena Keller, Emilia Oueis, Amninder Kaur, et al.
Journal of Hepatology|February 16, 2019
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitorsDominic H Banda, Paula M Perin, Richard J P Brown, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
Antimicrobial Resistance and Infection Control|February 17, 2018
Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological diseaseClaas Baier, Sibylle Haid, Andreas Beilken, et al.
Plos One|September 13, 2011
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virusThomas von Hahn, Andreas Schulze, Ivan Chicano Wust, et al.
Journal of Virology|November 11, 2011
Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitopeMarianne Ruhl, Patrick Chhatwal, Heiko Strathmann, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33Alexander W Tarr, Ania M Owsianka, Judith M Timms, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Adapted hepatitis C virus clone infects innate immunity-deficient mouse hepatocytes with minimal human HCV entry factorsJulie Ann Sheldon, Melina Winkler, Qinggong Yuan, et al.
Plos One|July 12, 2014
Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodiesMilena Lange, Melanie Fiedler, Dorothea Bankwitz, et al.
Mbio|May 18, 2017
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2Ieva Vasiliauskaite, Ania Owsianka, Patrick England, et al.
European Journal of Medicinal Chemistry|April 8, 2025
Unlocking the antiviral arsenal: Structure-guided optimization of small-molecule inhibitors against RSV and hCoV-229EChristina Karhan, Svenja M Sake, Antonia P Gunesch, et al.
Angewandte Chemie (International Ed. in English)|November 24, 2022
Persicamidines-Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against CoronavirusesLena Keller, Emilia Oueis, Amninder Kaur, et al.
Journal of Hepatology|February 16, 2019
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitorsDominic H Banda, Paula M Perin, Richard J P Brown, et al.
Pageof 21